- Home
- NCNA vs RDHL Comparison
NCNA vs RDHL Comparison
Compare NCNA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- RDHL
- Stock Information
- Founded
- NCNA 1997
- RDHL 2009
- Country
- NCNA United Kingdom
- RDHL Israel
- Employees
- NCNA N/A
- RDHL N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- RDHL Health Care
- Exchange
- NCNA Nasdaq
- RDHL Nasdaq
- Market Cap
- NCNA 4.5M
- RDHL 3.8M
- IPO Year
- NCNA 2017
- RDHL N/A
- Fundamental
- Price
- NCNA $0.05
- RDHL $1.99
- Analyst Decision
- NCNA Buy
- RDHL
- Analyst Count
- NCNA 2
- RDHL 0
- Target Price
- NCNA $25.00
- RDHL N/A
- AVG Volume (30 Days)
- NCNA 162.0M
- RDHL 214.4K
- Earning Date
- NCNA 06-02-2025
- RDHL 04-10-2025
- Dividend Yield
- NCNA N/A
- RDHL N/A
- EPS Growth
- NCNA N/A
- RDHL N/A
- EPS
- NCNA N/A
- RDHL N/A
- Revenue
- NCNA N/A
- RDHL $8,042,999.00
- Revenue This Year
- NCNA N/A
- RDHL $381.91
- Revenue Next Year
- NCNA N/A
- RDHL N/A
- P/E Ratio
- NCNA N/A
- RDHL N/A
- Revenue Growth
- NCNA N/A
- RDHL 23.17
- 52 Week Low
- NCNA $0.03
- RDHL $1.71
- 52 Week High
- NCNA $10.79
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- NCNA 37.23
- RDHL 51.03
- Support Level
- NCNA $0.04
- RDHL $1.82
- Resistance Level
- NCNA $0.06
- RDHL $1.93
- Average True Range (ATR)
- NCNA 0.01
- RDHL 0.08
- MACD
- NCNA 0.03
- RDHL 0.04
- Stochastic Oscillator
- NCNA 59.60
- RDHL 100.00
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.